Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SGP

SpyGlass Pharma Inc

20.88

Jul 23 • 3:59 PM ET +0.34 (1.66%)

20.88

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR RYTM INCY NUVL BMRN VKTX KRYS AXSM MDGL NBIX

| Held by: VTI IWM VGSR VXF IWO VTWO SCHA IWC SBIO IWN

Scroll to Statements

Index	RUT
Market Cap	698.09M
Enterprise Value	448.70M
Income	-
Sales	-
Book/sh	7.48
Cash/sh	7.51
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	65
IPO	Feb 06, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.79
P/C	2.78
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	38.00
Current Ratio	38.00
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.69
EPS next Q	-0.51
EPS this Y	87.35%
EPS next Y	-18.13%
EPS next 5Y	43.50%
EPS past 3/5Y	-69.04% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	May 14 AMC
EPS/Sales Surpr.	-37.15% -

Insider Own	58.27%
Insider Trans	245.48%
Inst Own	38.29%
Inst Trans	25.11%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.63%
SMA50	3.64%
SMA200	-9.85%
Trades

Shs Outstand	33.43M
Shs Float	13.95M
Short Float	9.40%
Short Ratio	11.90
Short Interest	1.31M
52W High	32.44 -35.64%
52W Low	17.06 22.39%
Volatility	7.05% 8.90%
ATR (14)	1.60
RSI (14)	53.62
Beta	-
Rel Volume	0.68
Avg Volume	110.18K
Volume	75,418

Perf Week	0.58%
Perf Month	6.15%
Perf Quarter	-14.74%
Perf Half Y	-
Perf YTD	-13.00%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	45.00
Prev Close	20.54
Price	20.88
Change	1.66%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-10-26	Initiated	H.C. Wainwright	Buy	$37
Mar-03-26	Initiated	Stifel	Buy	$42
Mar-03-26	Initiated	Leerink Partners	Outperform	$42
Mar-03-26	Initiated	Jefferies	Buy	$62
Mar-03-26	Initiated	Citigroup	Buy	$42

Jun-15-26 08:00AM	SpyGlass Pharma Appoints Shannon Trevino as General Counsel (GlobeNewswire)
Jun-02-26 08:00AM	SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing (GlobeNewswire)
May-21-26 08:00AM	SpyGlass Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-18-26 08:00AM	SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System (GlobeNewswire)
May-14-26 04:05PM	SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
04:05PM	Loading…
Mar-26-26 04:05PM	SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update (GlobeNewswire) -10.28%
Mar-09-26 08:00AM	SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System (GlobeNewswire)
Mar-04-26 08:00AM	SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit (GlobeNewswire)
Mar-03-26 09:33AM	MongoDB downgraded, Block upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Block, CrowdStrike, Fortinet, MongoDB, Mosaic, Palo Alto Networks, Unity Software, and More (24/7 Wall St.)
Feb-16-26 08:40AM	Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders (24/7 Wall St.)
Feb-09-26 04:05PM	SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +6.30%

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

Co-FounderDr. Malik Y. Kahook M.D.

CEO & DirectorMr. Patrick H. Mooney

Chief Research & Development OfficerDr. Chetan Pujara Ph.D.

Co-founder & Chief Technology AdvisorMr. Glenn Sussman

Chief Financial OfficerDr. Jean-Frederic Viret Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 09 '26	Buy	16.00	3,690,000	59,040,000	5,966,439	Feb 11 05:15 PM
Behbahani Ali	Director	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
Florence Anthony A. Jr.	10% Owner	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
BASKETT FOREST	10% Owner	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
New Enterprise Associates 17,	10% Owner	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
Yang Rick	10% Owner	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
Makhzoumi Mohamad	10% Owner	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
SANDELL SCOTT D	10% Owner	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
Chang Carmen	10% Owner	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
Walker Paul Edward	10% Owner	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
Mathers Edward T	10% Owner	Feb 09 '26	Buy	16.00	937,500	15,000,000	6,035,038	Feb 11 04:30 PM
Pardo Geoffrey B	Director	Feb 09 '26	Buy	16.00	312,500	5,000,000	2,187,513	Feb 11 04:09 PM
Khan Bilal Arshad	Director	Feb 09 '26	Buy	16.00	115,000	1,840,000	251,427	Feb 11 04:07 PM
Khan Bilal Arshad	Director	Feb 09 '26	Buy	16.00	20,000	320,000	25,450	Feb 11 04:07 PM
Nielsen Kirk G.	Director	Feb 09 '26	Buy	16.00	165,000	2,640,000	3,310,619	Feb 10 06:09 PM
Vensana Capital I GP, LLC	10% Owner	Feb 09 '26	Buy	16.00	165,000	2,640,000	3,310,619	Feb 10 06:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGP

SpyGlass Pharma Inc

Upgrade your Finviz experience